Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4283849 | 0.95 | BACE1 (0.58) | BACE1 | |
| SCHEMBL4146199 | 0.90 | BACE1 (0.61) | BACE1 | |
| SCHEMBL13879662 | 0.85 | BACE1 (0.71) | BACE1 | |
| Hydrochloric Acid SCHEMBL4275531 | 0.84 | BACE1 (0.70) | BACE1 | |
| SCHEMBL4141837 | 0.83 | BACE1 (0.65) | BACE1 | |
| SCHEMBL4137189 | 0.82 | BACE1 (0.72) | BACE1 | |
| SCHEMBL4148155 | 0.82 | BACE1 (0.72) | BACE1 | |
| SCHEMBL4150043 | 0.81 | BACE1 (0.71) | BACE1 | |
| SCHEMBL4155078 | 0.81 | BACE1 (0.67) | BACE1 | |
| SCHEMBL4146396 | 0.80 | BACE1 (0.61) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2007114771-A1 | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.